HIT Consultant November 13, 2024
What You Should Know:
– Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.
– This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.
Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery
Genesis Therapeutics, an AI-focused biotechnology company headquartered in Burlingame, CA, is revolutionizing small molecule drug discovery through its proprietary generative and predictive AI platform, **GEMS (Genesis Exploration of Molecular Space)**. GEMS integrates cutting-edge AI methodologies, including language models, diffusion models, and physical machine learning (ML) simulations, to generate and optimize molecules targeting complex biological structures.
Key Highlights of...
Today's Sponsors
Today's Sponsor